Back to search results

Observational Study on GLP-1RA Effects in Midlife Women

This observational study is looking at how GLP-1RA medications, which are used for weight loss, affect body composition (like lean muscle mass) and bone health in women aged 35 to 60. Researchers are also interested in how estrogen levels might play a role. You could be eligible if you are a woman between these ages, have a certain BMI, and are newly starting a GLP-1RA medication. The study will measure your body weight, body composition, and bone mineral density over a 6-month period to see what changes occur. The current status of this study is unclear.

Study design
This is an observational study with a planned enrollment of 50 women. It is not a randomized trial, meaning participants are not assigned to different treatment groups.
What's involved
The study will involve measurements of your body weight, body composition, and bone mineral density at baseline and through a 6-month visit.
Compensation
Not stated in the trial record.
Follow-up
Participants will be followed for 6 months, with measurements taken at baseline and through the 6-month visit.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07422987

GLP-1RA Effects on Lean Mass and Bone Health in Midlife Women

Active, Not Recruiting
Not specifiedAges 35–60Observational
University of Kansas Medical Center
~50 participants
Updated 2026-08-07 on ClinicalTrials.gov

At a glance

Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Body weight
Measured over Baseline through 6-month visit
+4 more outcomes measured

Conditions

Body Composition
Muscle Function
GLP-1
Estrogen Level

Explore related trials

Obesity

Where it's being run

1 sites across 1 states
Kansas1

Study leadership

  • Johanna Finkle, MD · PRINCIPAL_INVESTIGATOR · University of Kansas Medical Center

Who to contact

This trial hasn't published a contact. View it on ClinicalTrials.gov

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Females
Age 35-60 year
BMI≥30 or BMI≥27 and at least one cardiometabolic risk factor (dyslipidemia, hypertension, obstructive sleep apnea, metabolic syndrome, fatty liver, PCOS)
Newly prescribed a GLP-1RA medication
English speaking
Body weight stable for the past 6 months

Exclusion

Pregnant women
Under age 35 or over age 60
Born male
Cannot consent for themselves
Cannot read and speak in English
Type 2 diabetes
Recently discontinued a GLP-1RA medication (less than 6-months since discontinuing)
Contraindications for taking a GLP-1 RA medication (personal or family history of medullary thyroid carcinoma, personal or family history of multiple endocrine neoplasia type 2, personal history of pancreatitis, pregnancy, hypersensitivity to the drug or any component of the drug, active suicidal ideation)
Currently taking aromatase inhibitors or selective estrogen receptor modulators (SERMs)

What this trial measures

  • Body weightBaseline through 6-month visit

    Assess changes in body weight by measuring weight on a calibrated scale

  • Body compositionBaseline through 6-month visit

    Assess changes in lean and fat mass and fat-free mass in kilograms by total body DXA scan

  • Bone mineral density (BMD)Baseline through 6-month visit

    Assess changes in bone mineral density (BMD) by completing femur DXA scans

  • Muscle functionBaseline through 6-month visit

    Assess muscle function changes in pounds by completing Grip strength tests

  • Muscle functionBaseline through 6-month visit

    Assess changes to muscle function by the number of repetitions achieved per 30-second Sit-to-stand test